Progressive hearing impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Midface retrusion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Motor delay
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Brachyturricephaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Malar flattening
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Short Stature, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Generalized osteoporosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |
Osteosarcoma of bone
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |
Childhood Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |
Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
Osteosarcoma of bone
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
Childhood Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Osteosarcoma of bone
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Childhood Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Tumor-induced bone was reduced in trigenic mice (Tie2<sup>cre</sup>/Osx<sup>f/f</sup>/SCID) with endothelial-specific deletion of osteoblast cell-fate determinant OSX compared with bigenic mice (Osx<sup>f/f</sup>/SCID).
|
28586644 |
2017 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The results revealed that proliferation, apoptosis and the mRNA expression levels of RUNX2 and SP7 in MDS-MSCs did not significantly change following treatment with decitabine compared with control MDS-MSCs.
|
31611955 |
2019 |
Osteogenesis Imperfecta
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the Sp7 gene in humans are associated with craniofacial anomalies and osteogenesis imperfecta.
|
29405385 |
2018 |
Craniofacial Abnormalities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Mutations of the Sp7 gene in humans are associated with craniofacial anomalies and osteogenesis imperfecta.
|
29405385 |
2018 |
Nodule
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Interestingly, rapamycin in rapamycin plus lipopolysaccharide (LPS)‑treated BMSCs significantly increased the gene expression levels of Sp7 transcription factor, runt related transcription factor 2, alkaline phosphatase (ALP) and collagen I (Col I), ALP activity, and calcium nodule at different time points in vitro, indicating that osteoblast differentiation occurs by rapamycin when BMSCs are exposed to LPS simultaneously.
|
28990080 |
2017 |
Peripheral ossifying fibroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of Osterix protein in the pathogenesis of peripheral ossifying fibroma.
|
28678972 |
2017 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |